442 related articles for article (PubMed ID: 15292336)
21. Ovarian cancer-related hypophosphatemic osteomalacia--a case report.
Lin HA; Shih SR; Tseng YT; Chen CH; Chiu WY; Hsu CY; Tsai KS
J Clin Endocrinol Metab; 2014 Dec; 99(12):4403-7. PubMed ID: 25181387
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
23. Tumor-induced osteomalacia: lessons learned.
Lewiecki EM; Urig EJ; Williams RC
Arthritis Rheum; 2008 Mar; 58(3):773-7. PubMed ID: 18311810
[TBL] [Abstract][Full Text] [Related]
24. [Rickets/Osteomalacia. Diagnosis of tumor-induced osteomalacia.].
Koga M; Ito N
Clin Calcium; 2018; 28(10):1351-1357. PubMed ID: 30269117
[TBL] [Abstract][Full Text] [Related]
25. Tumour-induced osteomalacia: a literature review and a case report.
Dadoniene J; Miglinas M; Miltiniene D; Vajauskas D; Seinin D; Butenas P; Kacergius T
World J Surg Oncol; 2016 Jan; 14(1):4. PubMed ID: 26744291
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
Seemann L; Padala SA; Mohammed A; Belayneh N
J Investig Med High Impact Case Rep; 2019; 7():2324709619895162. PubMed ID: 31850815
[TBL] [Abstract][Full Text] [Related]
27. Tumor-induced Osteomalacia: A Systematic Review and Individual Patient's Data Analysis.
Rendina D; Abate V; Cacace G; D'Elia L; De Filippo G; Del Vecchio S; Galletti F; Cuocolo A; Strazzullo P
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3428-e3436. PubMed ID: 35468192
[TBL] [Abstract][Full Text] [Related]
28. [Tumor-induced Hypophosphatemic Osteomalacia Caused by a Chest Wall Tumor].
Kin Y; Ogawa H; Matsumoto G; Mitsui S; Matsumoto T; Nishioka Y; Sakai S; Kimura K; Shimizu N; Hokka D; Tanaka Y; Maniwa Y
Kyobu Geka; 2019 Aug; 72(8):570-573. PubMed ID: 31353346
[TBL] [Abstract][Full Text] [Related]
29. Tumor-induced osteomalacia.
Florenzano P; Gafni RI; Collins MT
Bone Rep; 2017 Dec; 7():90-97. PubMed ID: 29021995
[TBL] [Abstract][Full Text] [Related]
30. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia.
Fukumoto S
Endocrinol Metab (Seoul); 2014 Jun; 29(2):136-43. PubMed ID: 25031885
[TBL] [Abstract][Full Text] [Related]
32. [Oncogenic osteomalacia: the role of the phosphatonins. Diagnostic usefulness of the Fibroblast Growth Factor 23 measurement in one patient].
Dupond JL; Magy N; Mahammedi M; Prie D; Gil H; Meaux-Ruault N; Kantelip B
Rev Med Interne; 2005 Mar; 26(3):238-41. PubMed ID: 15777586
[TBL] [Abstract][Full Text] [Related]
33. Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report.
Tartaglia F; Minisola S; Sgueglia M; Blasi S; Brunelli D; Degli Effetti E; Maturo A; Cola A; Custureri F; Campana FP
G Chir; 2006; 27(1-2):9-13. PubMed ID: 16608626
[TBL] [Abstract][Full Text] [Related]
34. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
Boland JM; Tebben PJ; Folpe AL
J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
[TBL] [Abstract][Full Text] [Related]
35. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia.
Ito N; Hidaka N; Kato H
Endocrinol Metab (Seoul); 2024 Apr; 39(2):255-261. PubMed ID: 38467164
[TBL] [Abstract][Full Text] [Related]
36. [Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].
Kinoshita Y; Fukumoto S
Clin Calcium; 2014 Aug; 24(8):1217-22. PubMed ID: 25065874
[TBL] [Abstract][Full Text] [Related]
37. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
38. Tumor-induced osteomalacia.
Jan de Beur SM
JAMA; 2005 Sep; 294(10):1260-7. PubMed ID: 16160135
[TBL] [Abstract][Full Text] [Related]
39. Occult phosphaturic mesenchymal tumour of femur cortex causing oncogenic osteomalacia - diagnostic challenges and clinical outcomes.
Dutta D; Pandey RK; Gogoi R; Solanki N; Madan R; Mondal A; Dogra S; Thapa P
Endokrynol Pol; 2018; 69(2):205-210. PubMed ID: 29442350
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
